Is clinical development prepared for the paradigm shift caused by COVID-19?
The COVID-19 pandemic has – without warning – turned clinical trial operations on its head, forcing the industry to re-evaluate how to engage with patients and acquire patient data without direct, in-person access. Biopharmaceutical companies, medical device companies, and contract research organizations (CROs) from around the world were surveyed to explore the impact on clinical trials in this new paradigm.Get the report
Research insights into how the pandemic is changing clinical trial operations
Organizations have accelerated their plans to shift to decentralized clinical trial models that leverage remote data collection technologies and processes to engage with patients, rather than in-person visits.Read the white paper
of individuals involved in clinical trials said that the COVID‑19 pandemic has accelerated their adoption of decentralized clinical trial methods.
*Based on a November 2020 survey of 252 global respondents involved in clinical trials.
The current rate of cost increase is unsustainable, and clinical leaders must challenge the existing model and enable new approaches to take hold.
Gartner, industry vision: life science CIOs must transform clinical development with digital trials . Refreshed 15 January 2020, published 21 August 2018
The Data Landscape
See how clinical trial planning is evolving to tackle the new challenges faced by sponsors and clinical research organizations.Plan to make a difference
Trials in Detail
Understand the major shifts taking place in how clinical trials are executed in times of unprecedented complexity.Decentralize your thinking